Ling Peng1, Xianghua Ye, Yun Zhou, Junyan Zhang, Qiong Zhao. 1. Department of Thoracic Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang Province, China.
Abstract
BACKGROUND: Bortezomib is a proteasome inhibitor which has demonstrated activity against recurrent or newly diagnosed multiple myeloma (MM) and mantle cell lymphoma. Peripheral neuropathy has been described with this agent, although the overall incidence and relative risk remain unclear. We performed a meta-analysis to calculate the incidence of peripheral neuropathy associated with the use of intravenous bortezomib in MM and lymphoma and to compare the relative risk compared with placebo. METHODS: We searched PubMed, Embase, Cochrane databases, and meeting proceedings from the American Society of Clinical Oncology (ASCO) for relevant clinical trials. Eligible studies included prospective phase 2 and 3 clinical trials with toxicity profile on peripheral neuropathy associated with intravenous bortezomib in patients with MM and lymphoma. Statistical analyses were done to calculate summary incidences, relative risks (RRs), and 95 % confidence intervals (CIs), employing fixed- or random-effects models depending on the heterogeneity of the included studies. RESULTS: Altogether, 34 clinical trials were selected for the meta-analysis, yielding a total of 6492 patients. The incidence of peripheral neuropathy (all grades) was 33.9 % (95 % CI, 29.9-38.5 %) and that of high-grade events was 8.1 % (95 % CI, 6.9-9.4 %). The relative risks of bortezomib-induced peripheral neuropathy compared to placebo were increased for all-grade (RR = 4.89; 95 % CI, 2.52-9.51) and high-grade (RR = 4.53; 95 % CI, 2.04-10.07) peripheral neuropathy (for randomized controlled trials only). Our analysis was also stratified by different underlying diseases, and patients with lymphoma had an increased incidence of all-grade peripheral neuropathy than those with MM when treated with intravenous bortezomib. CONCLUSIONS: Treatment with intravenous bortezomib is associated with an increased risk of developing peripheral neuropathy.
BACKGROUND:Bortezomib is a proteasome inhibitor which has demonstrated activity against recurrent or newly diagnosed multiple myeloma (MM) and mantle cell lymphoma. Peripheral neuropathy has been described with this agent, although the overall incidence and relative risk remain unclear. We performed a meta-analysis to calculate the incidence of peripheral neuropathy associated with the use of intravenous bortezomib in MM and lymphoma and to compare the relative risk compared with placebo. METHODS: We searched PubMed, Embase, Cochrane databases, and meeting proceedings from the American Society of Clinical Oncology (ASCO) for relevant clinical trials. Eligible studies included prospective phase 2 and 3 clinical trials with toxicity profile on peripheral neuropathy associated with intravenous bortezomib in patients with MM and lymphoma. Statistical analyses were done to calculate summary incidences, relative risks (RRs), and 95 % confidence intervals (CIs), employing fixed- or random-effects models depending on the heterogeneity of the included studies. RESULTS: Altogether, 34 clinical trials were selected for the meta-analysis, yielding a total of 6492 patients. The incidence of peripheral neuropathy (all grades) was 33.9 % (95 % CI, 29.9-38.5 %) and that of high-grade events was 8.1 % (95 % CI, 6.9-9.4 %). The relative risks of bortezomib-induced peripheral neuropathy compared to placebo were increased for all-grade (RR = 4.89; 95 % CI, 2.52-9.51) and high-grade (RR = 4.53; 95 % CI, 2.04-10.07) peripheral neuropathy (for randomized controlled trials only). Our analysis was also stratified by different underlying diseases, and patients with lymphoma had an increased incidence of all-grade peripheral neuropathy than those with MM when treated with intravenous bortezomib. CONCLUSIONS: Treatment with intravenous bortezomib is associated with an increased risk of developing peripheral neuropathy.
Authors: Robert Z Orlowski; Arnon Nagler; Pieter Sonneveld; Joan Bladé; Roman Hajek; Andrew Spencer; Jesús San Miguel; Tadeusz Robak; Anna Dmoszynska; Noemi Horvath; Ivan Spicka; Heather J Sutherland; Alexander N Suvorov; Sen H Zhuang; Trilok Parekh; Liang Xiu; Zhilong Yuan; Wayne Rackoff; Jean-Luc Harousseau Journal: J Clin Oncol Date: 2007-08-06 Impact factor: 44.544
Authors: A Conconi; G Martinelli; A Lopez-Guillermo; P L Zinzani; A J M Ferreri; L Rigacci; L Devizzi; U Vitolo; S Luminari; F Cavalli; E Zucca Journal: Ann Oncol Date: 2010-09-01 Impact factor: 32.976
Authors: Vincent Ribrag; Hervé Tilly; Olivier Casasnovas; André Bosly; Reda Bouabdallah; Richard Delarue; François Boue; Dominique Bron; Pierre Feugier; Corinne Haioun; Firtz Offner; Bertrand Coiffier Journal: Eur J Cancer Date: 2012-12-25 Impact factor: 9.162
Authors: Jatin Shah; Joan Bladé; Pieter Sonneveld; Jean-Luc Harousseau; Keith Lantz; Anil Londhe; Colin Lowery; Robert Z Orlowski Journal: Cancer Date: 2011-02-15 Impact factor: 6.860
Authors: Nicholas Di Bella; Raymond Taetle; Kathryn Kolibaba; Thomas Boyd; Robert Raju; David Barrera; Ernest W Cochran; Philip Y Dien; Roger Lyons; Peter J Schlegel; Svetislava J Vukelja; Julie Boston; Kristi A Boehm; Yunfei Wang; Lina Asmar Journal: Blood Date: 2009-11-19 Impact factor: 22.113
Authors: John D Hainsworth; David R Spigel; John Barton; Cindy Farley; Marshall Schreeder; Jeremy Hon; F Anthony Greco Journal: Cancer Date: 2008-08-15 Impact factor: 6.860
Authors: Kristie A Blum; Jeffrey L Johnson; Donna Niedzwiecki; George P Canellos; Bruce D Cheson; Nancy L Bartlett Journal: Leuk Lymphoma Date: 2007-07
Authors: Laurent Garderet; Simona Iacobelli; Philippe Moreau; Mamoun Dib; Ingrid Lafon; Dietger Niederwieser; Tamas Masszi; Jean Fontan; Mauricette Michallet; Alois Gratwohl; Giuseppe Milone; Chantal Doyen; Brigitte Pegourie; Roman Hajek; Philippe Casassus; Brigitte Kolb; Carine Chaleteix; Bernd Hertenstein; Francesco Onida; Heinz Ludwig; Nicolas Ketterer; Christian Koenecke; Marleen van Os; Mohamad Mohty; Andrew Cakana; Norbert Claude Gorin; Theo de Witte; Jean Luc Harousseau; Curly Morris; Gösta Gahrton Journal: J Clin Oncol Date: 2012-05-14 Impact factor: 44.544
Authors: Grace L Smith; Maria A Lopez-Olivo; Pragati G Advani; Matthew S Ning; Yimin Geng; Sharon H Giordano; Robert J Volk Journal: J Natl Compr Canc Netw Date: 2019-10-01 Impact factor: 11.908
Authors: Marie Selvy; Nicolas Kerckhove; Bruno Pereira; Fantine Barreau; Daniel Nguyen; Jérôme Busserolles; Fabrice Giraudet; Aurélie Cabrespine; Carine Chaleteix; Martin Soubrier; Jacques-Olivier Bay; Richard Lemal; David Balayssac Journal: Front Pharmacol Date: 2021-04-22 Impact factor: 5.810